CL2023002495A1 - Anticuerpos anti-cd38 para su uso en el tratamiento del rechazo de trasplante mediado por anticuerpos - Google Patents

Anticuerpos anti-cd38 para su uso en el tratamiento del rechazo de trasplante mediado por anticuerpos

Info

Publication number
CL2023002495A1
CL2023002495A1 CL2023002495A CL2023002495A CL2023002495A1 CL 2023002495 A1 CL2023002495 A1 CL 2023002495A1 CL 2023002495 A CL2023002495 A CL 2023002495A CL 2023002495 A CL2023002495 A CL 2023002495A CL 2023002495 A1 CL2023002495 A1 CL 2023002495A1
Authority
CL
Chile
Prior art keywords
antibody
treatment
antibodies
transplant rejection
mediated transplant
Prior art date
Application number
CL2023002495A
Other languages
English (en)
Spanish (es)
Inventor
Steidl Stefan
Härtle Stefan
Boxhammer Rainer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of CL2023002495A1 publication Critical patent/CL2023002495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CL2023002495A 2021-03-01 2023-08-23 Anticuerpos anti-cd38 para su uso en el tratamiento del rechazo de trasplante mediado por anticuerpos CL2023002495A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21159860 2021-03-01

Publications (1)

Publication Number Publication Date
CL2023002495A1 true CL2023002495A1 (es) 2023-12-29

Family

ID=74844778

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002495A CL2023002495A1 (es) 2021-03-01 2023-08-23 Anticuerpos anti-cd38 para su uso en el tratamiento del rechazo de trasplante mediado por anticuerpos

Country Status (12)

Country Link
US (1) US20240228654A9 (cg-RX-API-DMAC10.html)
EP (1) EP4301779A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024507986A (cg-RX-API-DMAC10.html)
KR (1) KR20230154239A (cg-RX-API-DMAC10.html)
AU (1) AU2022230717A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023016352A2 (cg-RX-API-DMAC10.html)
CA (1) CA3209172A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023002495A1 (cg-RX-API-DMAC10.html)
IL (1) IL304692A (cg-RX-API-DMAC10.html)
MX (1) MX2023009868A (cg-RX-API-DMAC10.html)
TW (1) TW202302642A (cg-RX-API-DMAC10.html)
WO (1) WO2022184676A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202545561A (zh) * 2024-01-16 2025-12-01 德商莫菲西斯有限責任公司 抗體的高度濃縮液體製劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
EP3313441B1 (en) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
WO2020185672A1 (en) 2019-03-08 2020-09-17 Cedars-Sinai Medical Center Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants
TWI924633B (zh) 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物

Also Published As

Publication number Publication date
WO2022184676A1 (en) 2022-09-09
TW202302642A (zh) 2023-01-16
BR112023016352A2 (pt) 2023-10-03
KR20230154239A (ko) 2023-11-07
IL304692A (en) 2023-09-01
CA3209172A1 (en) 2022-09-09
EP4301779A1 (en) 2024-01-10
US20240228654A9 (en) 2024-07-11
US20240132618A1 (en) 2024-04-25
AU2022230717A1 (en) 2023-09-14
JP2024507986A (ja) 2024-02-21
MX2023009868A (es) 2023-08-29

Similar Documents

Publication Publication Date Title
EA202091809A1 (ru) Агонистические антитела против pd-1 и их применение
CR20200566A (es) Anticuerpos anti-sirpa y metodos de utilización de los mismos
CL2020002613A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2021002389A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296)
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
CL2022000230A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
CL2018002998A1 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
PE20190261A1 (es) Anticuerpos que reconocen tau
UY36692A (es) Anticuerpos anti-cd40 y usos de los mismos
AR079458A2 (es) Anticuerpo monoclonal quimerico que se une a cd45
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
EA201390725A1 (ru) Молчащие fc-варианты анти-cd40 антител
EA201890578A1 (ru) Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
CL2023003696A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
MX2021011181A (es) Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
MX2020004806A (es) Composiciones y métodos para el agotamiento de células cd2+.
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
AR124130A1 (es) Variantes de anticuerpos bovinos
EA201891594A1 (ru) Антитела к il-17c
ZA202305072B (en) Cd1a antibodies and uses thereof
CO2022014745A2 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso
ZA202006216B (en) Antibodies targeting glycoprotein vi